These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 23747811)

  • 1. Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure-activity relationship study.
    Thanigaimalai P; Konno S; Yamamoto T; Koiwai Y; Taguchi A; Takayama K; Yakushiji F; Akaji K; Kiso Y; Kawasaki Y; Chen SE; Naser-Tavakolian A; Schön A; Freire E; Hayashi Y
    Eur J Med Chem; 2013 Jul; 65():436-47. PubMed ID: 23747811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies.
    Thanigaimalai P; Konno S; Yamamoto T; Koiwai Y; Taguchi A; Takayama K; Yakushiji F; Akaji K; Chen SE; Naser-Tavakolian A; Schön A; Freire E; Hayashi Y
    Eur J Med Chem; 2013 Oct; 68():372-84. PubMed ID: 23994330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety.
    Konno S; Thanigaimalai P; Yamamoto T; Nakada K; Kakiuchi R; Takayama K; Yamazaki Y; Yakushiji F; Akaji K; Kiso Y; Kawasaki Y; Chen SE; Freire E; Hayashi Y
    Bioorg Med Chem; 2013 Jan; 21(2):412-24. PubMed ID: 23245752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of a series of serine derivatives as small molecule inhibitors of the SARS coronavirus 3CL protease.
    Konno H; Wakabayashi M; Takanuma D; Saito Y; Akaji K
    Bioorg Med Chem; 2016 Mar; 24(6):1241-54. PubMed ID: 26879854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a non-prime site substituent and warheads combined with a decahydroisoquinolin scaffold as a SARS 3CL protease inhibitor.
    Ohnishi K; Hattori Y; Kobayashi K; Akaji K
    Bioorg Med Chem; 2019 Jan; 27(2):425-435. PubMed ID: 30558861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor.
    Yang S; Chen SJ; Hsu MF; Wu JD; Tseng CT; Liu YF; Chen HC; Kuo CW; Wu CS; Chang LW; Chen WC; Liao SY; Chang TY; Hung HH; Shr HL; Liu CY; Huang YA; Chang LY; Hsu JC; Peters CJ; Wang AH; Hsu MC
    J Med Chem; 2006 Aug; 49(16):4971-80. PubMed ID: 16884309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.
    Zhu L; George S; Schmidt MF; Al-Gharabli SI; Rademann J; Hilgenfeld R
    Antiviral Res; 2011 Nov; 92(2):204-12. PubMed ID: 21854807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.
    Ramajayam R; Tan KP; Liu HG; Liang PH
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3569-72. PubMed ID: 20494577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovering severe acute respiratory syndrome coronavirus 3CL protease inhibitors: virtual screening, surface plasmon resonance, and fluorescence resonance energy transfer assays.
    Chen L; Chen S; Gui C; Shen J; Shen X; Jiang H
    J Biomol Screen; 2006 Dec; 11(8):915-21. PubMed ID: 17092912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of SARS-CoV 3CL protease by flavonoids.
    Jo S; Kim S; Shin DH; Kim MS
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):145-151. PubMed ID: 31724441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.
    Pillaiyar T; Manickam M; Namasivayam V; Hayashi Y; Jung SH
    J Med Chem; 2016 Jul; 59(14):6595-628. PubMed ID: 26878082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element.
    Galasiti Kankanamalage AC; Kim Y; Damalanka VC; Rathnayake AD; Fehr AR; Mehzabeen N; Battaile KP; Lovell S; Lushington GH; Perlman S; Chang KO; Groutas WC
    Eur J Med Chem; 2018 Apr; 150():334-346. PubMed ID: 29544147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus.
    Goetz DH; Choe Y; Hansell E; Chen YT; McDowell M; Jonsson CB; Roush WR; McKerrow J; Craik CS
    Biochemistry; 2007 Jul; 46(30):8744-52. PubMed ID: 17605471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease.
    Shao YM; Yang WB; Kuo TH; Tsai KC; Lin CH; Yang AS; Liang PH; Wong CH
    Bioorg Med Chem; 2008 Apr; 16(8):4652-60. PubMed ID: 18329272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors.
    Yang Q; Chen L; He X; Gao Z; Shen X; Bai D
    Chem Pharm Bull (Tokyo); 2008 Oct; 56(10):1400-5. PubMed ID: 18827378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.
    Regnier T; Sarma D; Hidaka K; Bacha U; Freire E; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2009 May; 19(10):2722-7. PubMed ID: 19362479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors.
    Shao YM; Yang WB; Peng HP; Hsu MF; Tsai KC; Kuo TH; Wang AH; Liang PH; Lin CH; Yang AS; Wong CH
    Chembiochem; 2007 Sep; 8(14):1654-7. PubMed ID: 17722121
    [No Abstract]   [Full Text] [Related]  

  • 18. Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and
    Bai B; Belovodskiy A; Hena M; Kandadai AS; Joyce MA; Saffran HA; Shields JA; Khan MB; Arutyunova E; Lu J; Bajwa SK; Hockman D; Fischer C; Lamer T; Vuong W; van Belkum MJ; Gu Z; Lin F; Du Y; Xu J; Rahim M; Young HS; Vederas JC; Tyrrell DL; Lemieux MJ; Nieman JA
    J Med Chem; 2022 Feb; 65(4):2905-2925. PubMed ID: 34242027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.
    Tsai KC; Chen SY; Liang PH; Lu IL; Mahindroo N; Hsieh HP; Chao YS; Liu L; Liu D; Lien W; Lin TH; Wu SY
    J Med Chem; 2006 Jun; 49(12):3485-95. PubMed ID: 16759091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents.
    Konno S; Kobayashi K; Senda M; Funai Y; Seki Y; Tamai I; Schäkel L; Sakata K; Pillaiyar T; Taguchi A; Taniguchi A; Gütschow M; Müller CE; Takeuchi K; Hirohama M; Kawaguchi A; Kojima M; Senda T; Shirasaka Y; Kamitani W; Hayashi Y
    J Med Chem; 2022 Feb; 65(4):2926-2939. PubMed ID: 34313428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.